---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-069045"
form_type: "8-K"
ticker: null
cik: "0001496323"
company_name: "IGM Biosciences, Inc."
filed_at: "2023-12-08T23:59:59+00:00"
generated_at: "2026-06-07T15:32:06.107156+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IGM Biosciences halts hematologic oncology programs, cuts workforce 22%, extends cash runway to Q2 2026

## Summary
- Reduces workforce by ~22%; focusing on DR5 agonist in colorectal cancer and T cell engagers in autoimmune diseases.
- Halts all hematologic oncology clinical development and targeted cytokine program; continues Sanofi collaboration.
- Plans to file IND for IGM-2644 (CD38 x CD3) for autoimmune disease in 2024.
- Cash runway now expected into Q2 2026; estimates $1.9M in employee-related restructuring charges.
- Enrollment continues in randomized aplitabart colorectal cancer trial (goal ~110 patients by Q1 2024).

## SEC filing metadata
- accession: 0000950170-23-069045
- form_type: 8-K
- cik: 0001496323
- company_name: IGM Biosciences, Inc.
- filed_at: 2023-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1496323/000095017023069045/0000950170-23-069045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1496323/000095017023069045/igms-20231205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-069045
- JSON: https://secwatch.observer/filing/0000950170-23-069045.json
- Plain text: https://secwatch.observer/filing/0000950170-23-069045.txt

## Key facts
- Restructurings & Charges
  IGM Biosciences, Inc. announced a restructuring with charges of approximately $1.9 million (approximately 22 percent).
  - Type: restructuring
  - Charge: approximately $1.9 million
  - Headcount: approximately 22 percent
  source text: The Company estimates it will incur approximately $1.9 million in employee-related restructuring charges as a result of the Strategic Refocusing, consisting of cash expenditures of $3.9 million from one-time employee benefits and severance costs, offset by non-cash benefits of $2.0 million related to the reversal of previously recognized incentive and stock-based compensation expense.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1496323/000095017023069045/0000950170-23-069045-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.